ZA202309162B - Chromosome interaction markers - Google Patents
Chromosome interaction markersInfo
- Publication number
- ZA202309162B ZA202309162B ZA2023/09162A ZA202309162A ZA202309162B ZA 202309162 B ZA202309162 B ZA 202309162B ZA 2023/09162 A ZA2023/09162 A ZA 2023/09162A ZA 202309162 A ZA202309162 A ZA 202309162A ZA 202309162 B ZA202309162 B ZA 202309162B
- Authority
- ZA
- South Africa
- Prior art keywords
- chromosome interaction
- interaction markers
- markers
- chromosome
- analysing
- Prior art date
Links
- 210000000349 chromosome Anatomy 0.000 title abstract 2
- 230000003993 interaction Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156659P | 2021-03-04 | 2021-03-04 | |
| US202163282284P | 2021-11-23 | 2021-11-23 | |
| PCT/GB2022/050561 WO2022185062A1 (en) | 2021-03-04 | 2022-03-03 | Chromosome interaction markers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202309162B true ZA202309162B (en) | 2025-03-26 |
Family
ID=80735500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2023/09162A ZA202309162B (en) | 2021-03-04 | 2023-09-28 | Chromosome interaction markers |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240229135A9 (enExample) |
| EP (1) | EP4301874B1 (enExample) |
| JP (1) | JP2024511292A (enExample) |
| KR (1) | KR20240006020A (enExample) |
| AU (1) | AU2022230780B2 (enExample) |
| BR (1) | BR112023017802A2 (enExample) |
| CA (1) | CA3209544A1 (enExample) |
| ES (1) | ES3029416T3 (enExample) |
| GB (1) | GB2618727B (enExample) |
| HU (1) | HUE071359T2 (enExample) |
| IL (1) | IL304883A (enExample) |
| PL (1) | PL4301874T3 (enExample) |
| TW (1) | TW202302862A (enExample) |
| WO (1) | WO2022185062A1 (enExample) |
| ZA (1) | ZA202309162B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202412610D0 (en) * | 2024-08-28 | 2024-10-09 | Oxford BioDynamics PLC | Screening method |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111511930B (zh) * | 2017-11-03 | 2024-11-22 | 牛津生物动力有限责任公司 | 通过染色体相互作用遗传调节免疫响应 |
| WO2020198676A1 (en) * | 2019-03-28 | 2020-10-01 | Bristol-Myers Squibb Company | Methods of treating tumor |
| GB2626699B (en) * | 2019-05-08 | 2024-11-20 | Oxford BioDynamics PLC | Chromosome Conformation Markers of Prostate Cancer and Lymphoma |
| WO2021228888A1 (en) * | 2020-05-12 | 2021-11-18 | Asylia Diagnostics | Biomarkers for hyperprogressive disease and therapy response after immunotherapy |
-
2022
- 2022-03-02 TW TW111107496A patent/TW202302862A/zh unknown
- 2022-03-03 BR BR112023017802A patent/BR112023017802A2/pt unknown
- 2022-03-03 ES ES22709783T patent/ES3029416T3/es active Active
- 2022-03-03 IL IL304883A patent/IL304883A/en unknown
- 2022-03-03 PL PL22709783.9T patent/PL4301874T3/pl unknown
- 2022-03-03 AU AU2022230780A patent/AU2022230780B2/en active Active
- 2022-03-03 JP JP2023553436A patent/JP2024511292A/ja active Pending
- 2022-03-03 KR KR1020237033851A patent/KR20240006020A/ko active Pending
- 2022-03-03 EP EP22709783.9A patent/EP4301874B1/en active Active
- 2022-03-03 US US18/547,579 patent/US20240229135A9/en active Pending
- 2022-03-03 HU HUE22709783A patent/HUE071359T2/hu unknown
- 2022-03-03 WO PCT/GB2022/050561 patent/WO2022185062A1/en not_active Ceased
- 2022-03-03 CA CA3209544A patent/CA3209544A1/en active Pending
- 2022-03-03 GB GB2313067.7A patent/GB2618727B/en active Active
-
2023
- 2023-09-28 ZA ZA2023/09162A patent/ZA202309162B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024511292A (ja) | 2024-03-13 |
| US20240229135A9 (en) | 2024-07-11 |
| BR112023017802A2 (pt) | 2023-12-12 |
| TW202302862A (zh) | 2023-01-16 |
| AU2022230780A1 (en) | 2023-10-12 |
| EP4301874C0 (en) | 2025-04-23 |
| HUE071359T2 (hu) | 2025-08-28 |
| ES3029416T3 (en) | 2025-06-24 |
| EP4301874B1 (en) | 2025-04-23 |
| GB202313067D0 (en) | 2023-10-11 |
| WO2022185062A1 (en) | 2022-09-09 |
| AU2022230780B2 (en) | 2024-05-23 |
| GB2618727A (en) | 2023-11-15 |
| US20240132959A1 (en) | 2024-04-25 |
| PL4301874T3 (pl) | 2025-06-23 |
| GB2618727B (en) | 2024-07-17 |
| KR20240006020A (ko) | 2024-01-12 |
| CA3209544A1 (en) | 2022-09-09 |
| EP4301874A1 (en) | 2024-01-10 |
| IL304883A (en) | 2023-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020051142A3 (en) | Methods of treating cancer | |
| AU2015205241A1 (en) | Method for operating blast furnace | |
| MX2020001278A (es) | Sintesis de compuestos de carbamoilpiridona policiclica. | |
| NZ732766A (en) | Process for the preparation of a diarylthiohydantoin compound | |
| AU2016277367A8 (en) | Aryl sulfonohydrazides | |
| IN2009DN05722A (enExample) | ||
| MY199800A (en) | Genetic regulation of immunoresponse by chromosome interactions | |
| CL2012003449A1 (es) | Procedimiento para aumentar la produccion de un yacimiento que comprende rocas las que contienen un mineral de sustancia valiosa que debe dejarse al descubierto por trituracion de las rocas, comprende realizacion de un proceso de perforacion por medio de un aparato de perforacion, creacion de un aerosol que comprende un polvo de perforacion. | |
| MX2016008259A (es) | Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa. | |
| MX2022000253A (es) | Proceso de fermentacion industrial para celulas microbianas mediante el uso de un precultivo de alimentacion por lotes. | |
| MX2023000970A (es) | Metodo de preparacion de aminofuranos. | |
| NZ702935A (en) | Process for making hydroxylated cyclopentylpyrimidine compounds | |
| GEP201706626B (en) | Synthesis of (s)-nifuratel | |
| WO2019224548A3 (en) | Methods for the production of methacrylates | |
| MY200184A (en) | Biomarker | |
| BR112021025588A2 (pt) | Processo para a preparação dos inibidores de canal de cloreto clc-1 | |
| IL279168B (en) | A process for the preparation of eribulin | |
| CL2021000663A1 (es) | Proceso para la producción de gas de síntesis. | |
| MY203765A (en) | Chromosome conformation markers of prostate cancer and lymphoma | |
| IN2014MU00195A (enExample) | ||
| AU2020344206A8 (en) | Diagnostic chromosome marker | |
| BR112023017802A2 (pt) | Marcadores de interação cromossômica | |
| GB2615481A8 (en) | Disease marker | |
| MX2023004094A (es) | Metodo para la preparacion de carbonilaminofuranos. | |
| MX2023010286A (es) | Proceso para preparar alquil-4-oxotetrahidrofuran-2-carboxilato. |